CL2011002217A1 - Suspension acuosa oral que comprende riluzol, un tensioactivo seleccionado de tensioactivos anionicos, tensioactivos no ionicos o una mezcla de ellos, y un agente de suspension seleccionado de arcillas esmectitas, celulosa microcristalina, gomas naturales o sus mezclas; y su uso para tratar esclerosis amiotrofica lateral. - Google Patents

Suspension acuosa oral que comprende riluzol, un tensioactivo seleccionado de tensioactivos anionicos, tensioactivos no ionicos o una mezcla de ellos, y un agente de suspension seleccionado de arcillas esmectitas, celulosa microcristalina, gomas naturales o sus mezclas; y su uso para tratar esclerosis amiotrofica lateral.

Info

Publication number
CL2011002217A1
CL2011002217A1 CL2011002217A CL2011002217A CL2011002217A1 CL 2011002217 A1 CL2011002217 A1 CL 2011002217A1 CL 2011002217 A CL2011002217 A CL 2011002217A CL 2011002217 A CL2011002217 A CL 2011002217A CL 2011002217 A1 CL2011002217 A1 CL 2011002217A1
Authority
CL
Chile
Prior art keywords
riluzole
mixtures
aqueous suspension
suspending agent
mixture
Prior art date
Application number
CL2011002217A
Other languages
English (en)
Inventor
Roberta Artico
Marco Adami
Jaime Moscoso
Tiziano Oldoni
Paolo Mascagni
Daniela Barbareschi
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40810549&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2011002217(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed filed Critical
Publication of CL2011002217A1 publication Critical patent/CL2011002217A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/428—Thiazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Inorganic Chemistry (AREA)
  • Pain & Pain Management (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Hospice & Palliative Care (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Psychiatry (AREA)
  • Dispersion Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Suspensión acuosa que comprende riluzol, al menos un tensoactivo y al menos un agente de suspensión, útil en el tratamiento de la esclerosis amiotrófica lateral.
CL2011002217A 2009-03-13 2011-09-08 Suspension acuosa oral que comprende riluzol, un tensioactivo seleccionado de tensioactivos anionicos, tensioactivos no ionicos o una mezcla de ellos, y un agente de suspension seleccionado de arcillas esmectitas, celulosa microcristalina, gomas naturales o sus mezclas; y su uso para tratar esclerosis amiotrofica lateral. CL2011002217A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP09425101A EP2228054A1 (en) 2009-03-13 2009-03-13 Riluzole aqueous suspensions

Publications (1)

Publication Number Publication Date
CL2011002217A1 true CL2011002217A1 (es) 2012-03-09

Family

ID=40810549

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2011002217A CL2011002217A1 (es) 2009-03-13 2011-09-08 Suspension acuosa oral que comprende riluzol, un tensioactivo seleccionado de tensioactivos anionicos, tensioactivos no ionicos o una mezcla de ellos, y un agente de suspension seleccionado de arcillas esmectitas, celulosa microcristalina, gomas naturales o sus mezclas; y su uso para tratar esclerosis amiotrofica lateral.

Country Status (21)

Country Link
US (1) US8765150B2 (es)
EP (2) EP2228054A1 (es)
JP (1) JP5607083B2 (es)
KR (1) KR101680175B1 (es)
CN (1) CN102341091B (es)
BR (1) BRPI1006418A2 (es)
CA (1) CA2748856C (es)
CL (1) CL2011002217A1 (es)
CO (1) CO6410281A2 (es)
CY (1) CY1113825T1 (es)
DK (1) DK2405890T3 (es)
ES (1) ES2400349T3 (es)
HR (1) HRP20130021T1 (es)
MX (1) MX2011008922A (es)
PE (1) PE20120649A1 (es)
PL (1) PL2405890T3 (es)
PT (1) PT2405890E (es)
RU (1) RU2498802C2 (es)
SI (1) SI2405890T1 (es)
SM (1) SMT201300022B (es)
WO (1) WO2010102923A2 (es)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101951220B1 (ko) 2011-07-13 2019-02-22 싸이토키네틱스, 인코포레이티드 조합 als 치료법
WO2013192610A2 (en) 2012-06-23 2013-12-27 Fox Chase Chemical Diversity Center, Inc. Pro-drugs of riluzole and their method of use for the treatment of amyotrophic lateral sclerosis
EP3023093B1 (en) * 2014-11-20 2017-07-26 S.I.I.T. S.r.l.-Servizio Internazionale Imballaggi Termosaldanti Medicinal preparation based on diosmectite
EA038518B1 (ru) * 2014-11-21 2021-09-09 Биохэйвен Фармасьютикал Холдинг Компани Лтд. Сублингвальный препарат рилузола
MX2017006454A (es) * 2014-11-21 2018-03-23 Biohaven Pharm Holding Co Ltd Administracion sublingual de riluzol.
US11911369B2 (en) * 2015-03-03 2024-02-27 Biohaven Therapeutics Ltd. Prodrugs of riluzole and their method of use
ITUB20155193A1 (it) * 2015-11-03 2017-05-03 Italfarmaco Spa Sospensioni orali di Givinostat fisicamente e chimicamente stabili
CN105726477B (zh) * 2016-03-01 2018-10-12 山东司邦得制药有限公司 一种小儿多潘立酮混悬液及其制备方法
CN108721325B (zh) * 2017-04-13 2020-03-06 辽宁大熊制药有限公司 蒙脱石混悬液及其制备方法
WO2019108594A1 (en) * 2017-11-28 2019-06-06 University Of Houston System Liquid formulations of riluzole for oral and intravenous use
CN111437256A (zh) * 2019-01-17 2020-07-24 北京万全德众医药生物技术有限公司 一种利鲁唑缓释口服混悬液
CN115025056A (zh) * 2022-06-27 2022-09-09 郑州大学第一附属医院 一种含有替加氟、吉莫斯特和奥替拉西钾的口腔崩解制剂

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CZ288492B6 (en) 1990-04-24 2001-06-13 Biota Scient Management Derivatives of alpha-D-neuraminic acid, process of their preparation, their use and pharmaceutical preparations based thereon
FR2688138B1 (fr) * 1992-03-06 1995-05-05 Rhone Poulenc Rorer Sa Application de l'amino-2 trifluoromethoxy-6 benzothiazole pour obtenir un medicament destine au traitement de la sclerose laterale amyotrophique.
AUPN605795A0 (en) * 1995-10-19 1995-11-09 F.H. Faulding & Co. Limited Analgesic pharmaceutical composition
FR2777781B1 (fr) * 1998-04-24 2004-04-09 Rhone Poulenc Rorer Sa Associations riluzole et l-dopa pour le traitement de la maladie de parkinson
US7374779B2 (en) * 1999-02-26 2008-05-20 Lipocine, Inc. Pharmaceutical formulations and systems for improved absorption and multistage release of active agents
EP1187612B1 (en) * 1999-06-04 2005-01-26 Vereniging Voor Christelijk Wetenschappelijk Onderwijs Use of riluzole for the treatment of multiple sclerosis
KR20020029098A (ko) * 1999-08-12 2002-04-17 피터 지. 스트링거 외부기생충박멸용 스피노신의 수성 현탁액 제제
US20030180352A1 (en) * 1999-11-23 2003-09-25 Patel Mahesh V. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
US6432992B1 (en) 2000-06-05 2002-08-13 Aventis Pharm Sa Use of riluzole or its salts for the prevention and treatment of adrenoleukodystrophy
US6613308B2 (en) * 2000-09-19 2003-09-02 Advanced Inhalation Research, Inc. Pulmonary delivery in treating disorders of the central nervous system
US6861413B2 (en) * 2001-05-22 2005-03-01 Pfizer Inc. Stable non-dihydrate azithromycin oral suspensions
CA2480826C (fr) 2002-04-09 2012-02-07 Flamel Technologies Formulation pharmaceutique orale sous forme de suspension aqueuse de microcapsules permettant la liberation modifiee de principe(s) actif(s)
ES2432117T3 (es) 2002-11-15 2013-11-29 Teva Pharmaceutical Industries Limited Uso de rasagilina con riluzol para tratar la esclerosis lateral amiotrófica
DE50304744D1 (de) 2003-04-28 2006-10-05 Biofrontera Bioscience Gmbh Verwendung von Riluzole kombiniert mit geeigneten Hilfs-und Zusatzstoffen zur Behandlung von Krankheiten, die durch eine Hyperproliferation von Keratinozyten gekennzeichnet sind, insbesondere Neurodermitis und Psoriasis
US9492541B2 (en) 2004-09-14 2016-11-15 Sovereign Pharmaceuticals, Llc Phenylepherine containing dosage form
US20050266032A1 (en) 2003-12-17 2005-12-01 Sovereign Pharmaceuticals, Ltd. Dosage form containing multiple drugs
AU2005218625A1 (en) 2004-03-03 2005-09-15 Teva Pharmaceutical Industries, Ltd. Combination therapy with glatiramer acetate and riluzole
US7691368B2 (en) * 2005-04-15 2010-04-06 Merial Limited Vaccine formulations
ITMI20061274A1 (it) * 2006-06-30 2008-01-01 Consiglio Nazionale Ricerche Vettori nanoparticellari lipidici contenenti riluzolo e composizioni farmaceutiche che li contengono
US9132071B2 (en) * 2006-07-28 2015-09-15 Santen Sas Compositions containing quaternary ammonium compounds

Also Published As

Publication number Publication date
PL2405890T3 (pl) 2013-04-30
HK1161985A1 (en) 2012-08-17
DK2405890T3 (da) 2013-02-04
CN102341091A (zh) 2012-02-01
EP2405890B1 (en) 2012-11-28
US8765150B2 (en) 2014-07-01
SMT201300022B (it) 2013-03-08
CY1113825T1 (el) 2016-07-27
WO2010102923A3 (en) 2011-03-03
PE20120649A1 (es) 2012-06-07
EP2405890A2 (en) 2012-01-18
ES2400349T3 (es) 2013-04-09
JP2012520254A (ja) 2012-09-06
SI2405890T1 (sl) 2013-02-28
BRPI1006418A2 (pt) 2016-11-29
CO6410281A2 (es) 2012-03-30
JP5607083B2 (ja) 2014-10-15
US20120039953A1 (en) 2012-02-16
CA2748856C (en) 2017-01-03
RU2498802C2 (ru) 2013-11-20
EP2228054A1 (en) 2010-09-15
HRP20130021T1 (hr) 2013-02-28
KR20120003854A (ko) 2012-01-11
CA2748856A1 (en) 2010-09-16
MX2011008922A (es) 2011-12-06
PT2405890E (pt) 2013-02-20
RU2011141422A (ru) 2013-04-20
WO2010102923A2 (en) 2010-09-16
CN102341091B (zh) 2013-08-07
KR101680175B1 (ko) 2016-11-28

Similar Documents

Publication Publication Date Title
CL2011002217A1 (es) Suspension acuosa oral que comprende riluzol, un tensioactivo seleccionado de tensioactivos anionicos, tensioactivos no ionicos o una mezcla de ellos, y un agente de suspension seleccionado de arcillas esmectitas, celulosa microcristalina, gomas naturales o sus mezclas; y su uso para tratar esclerosis amiotrofica lateral.
GT200600465A (es) Composición para detergente líquido
AR059456A1 (es) Agente benefico que comprende particulas de suministro
CL2011000561A1 (es) Formulacion farmaceutica que comprende un anticuerpo contra p-selectina, un regulador de ph, un agente tensoactivo, un estabilizador; uso de dicha formulacion para tratar el asma o alergia.
BR112014000382A2 (pt) uso de microemulsões em composições cosméticas de limpeza
AR075355A1 (es) Particula de suministro que contiene agentes beneficos
AR063892A1 (es) Particulas de suministro que contienen agentes beneficos
CL2011001811A1 (es) Un metodo para tratar un paciente que ha sufrido un infarto agudo al miocardio que comprende el uso de un agente antifibrotico.
AR079538A1 (es) Composicion que comprende microcapsulas
MX2017001612A (es) Composicion detergente para lavanderia.
PE20181218A1 (es) Modificadores de espuma para suspensiones cementosas, metodos y productos
MX2009006415A (es) Sistemas surfactantes espesados comprendiendo microfibras de celulosa y metodos para la produccion de los mismos.
AR050028A1 (es) Composiciones blanqueadoras dentales y sistemas para su administracion
MX2013002058A (es) Composicion de tratamiento para cabello.
CL2011003113A1 (es) Composicion adyuvante acuosa que comprende un agonista de tlr-4 y una saponina y un agente de isotonicidad no ionico; proceso para la preparacion de una composicion inmunogenica.
MX2020011849A (es) Detergente enzimático de multiples usos y métodos de estabilizar una solución de uso.
PE20140255A1 (es) Tableta dispersable en forma oral
CL2012000446A1 (es) Uso de una formulación vesicular tópica que comprende uno o más fosfolípidos y uno o más tensoactivos en una razón molar de 1:1 a 25:1 de fosfolípidos a tensoactivos, para el tratamiento de trastornos dermatosos inflamatorios.
CL2008001059A1 (es) Composicion de limpieza de superficie dura que es al menos parcialmente transparente o traslucida, que comprende 50 - 80% de agente tensioactivo no ionico op anfoterico y 1 - 50% de perfume; metodo para proporcionar higiene en un inodoro; y uso
CL2008003261A1 (es) Composición farmaceutica en forma de suspension que comprende carisbamato, hipromelosa y agua; proceso para prepararla y su uso para tratar enfermedades tales como epilepsia, dolor neuropatico, temblor y esquizofrenia, entre otras.
AR075063A1 (es) Composiciones que comprenden agentes tensoactivos no ionicos y zwiterionicos
MX361823B (es) Composición de limpieza.
CL2012003529A1 (es) Composicion para el cuidado oral que puede formar espuma, no aireada, que comprende de 1,5% de surfactante anionico (en peso), agente de limpieza abrasivo e hidrofobina; uso de hidrofobina para potenciar la suavidad en una composicion para el cuidado oral, capaz de formar espuma, no aireada.
MY165827A (en) Microfibrous cellulose and alkaline earth metal ion structured surfactant composition
MX378600B (es) Composicion limpiadora.